Keenova Therapeutics plc

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (24.02.2026)
HOCH Abgang Schlüsselpersonen (20.02.2026)
DatumMeldungSchwereFilingAuszug
24.02.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
20.02.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
25.08.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
14.08.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
06.08.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
01.08.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSECand is incorporated herein by reference.   Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
07.07.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
16.05.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
05.12.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC, 2023 are each incorporated herein by reference. Item 5.02    Departure of Directors or Certain Officers; Election of D
02.02.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
26.01.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
15.11.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSECch are incorporated herein by reference.   Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
13.11.2023Item 1.03 — Insolvenz / KonkursKRITISCHSEC      Item 1.03. Bankruptcy or Receivership.   As previously disclosed, on August 28, 2023, Mallinckrodt plc (in examina
10.10.2023Item 1.03 — Insolvenz / KonkursKRITISCHSECnt Report on Form 8-K and incorporated into this Item 1.03 by reference. Capitalized terms used but not defined herein h
28.08.2023Item 1.03 — Insolvenz / KonkursKRITISCHSEC      Item 1.03. Bankruptcy or Receivership.   As contemplated by the previously announced restructuring support agreeme
07.07.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Com
21.06.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C

Stammdaten

Unternehmen & Branche

NameKeenova Therapeutics plc
Ticker
CIK0001567892
SIC2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP
ISIN
Typ

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-04-17Silver Point Capital L.P.10% OwnerOpen Market Purchase410,00090.5037,105,000.00+271,0%
2026-04-15Silver Point Capital L.P.10% OwnerOpen Market Purchase275,00088.5024,337,500.00+177,7%
2026-01-07Silver Point Capital L.P.10% OwnerOpen Market Purchase250,00092.2523,062,500.00+168,4%
2025-12-08Silver Point Capital L.P.10% OwnerOpen Market Purchase130,97488.7511,623,942.50+84,9%
2025-11-19Silver Point Capital L.P.10% OwnerOpen Market Purchase42,00088.883,732,750.00+27,3%
2025-11-17Silver Point Capital L.P.10% OwnerOpen Market Purchase26,00088.882,310,750.00+16,9%
2025-11-10Silver Point Capital L.P.10% OwnerOpen Market Purchase290,00093.7527,187,500.00+198,6%
2025-08-06GOLDENTREE ASSET MANAGEMENT LP10% OwnerOpen Market Purchase6,70092.50619,750.00+4,5%
2025-08-04GOLDENTREE ASSET MANAGEMENT LP10% OwnerOpen Market Purchase30,00087.252,617,500.00+19,1%
2025-08-01GOLDENTREE ASSET MANAGEMENT LP10% OwnerOpen Market Purchase50,00086.504,325,000.00+31,6%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.

Hinweis

Erweitert ×